04.11.14
Quantel Medical has received CE Mark approval for its Optimis Fusion integrated laser platform. The Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma.
Quantel will immediately begin selling the product in all CE Mark-approved countries. U.S. Food and Drug Administration approval
Quantel will immediately begin selling the product in all CE Mark-approved countries. U.S. Food and Drug Administration approval
is expected sometime this year.
The Fusion’s SLT mode incorporates the most advanced laser technology available to provide a first-choice treatment for managing glaucoma and lowering intraocular pressure, according to Quantel. SLT therapy targets melanin-rich cells, which absorb the laser energy to induce a healing response that begins to improve the function of the trabecular meshwork. The laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage. Due to the gentle delivery and no permanent destruction to the trabecular meshwork, SLT leaves the structures intact and can be repeated if necessary.
The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.
“This approval constitutes a critical milestone for our medical laser business,” said Jean-Marc Gendre, CEO of Quantel Medical. “We are proud to introduce an engineering breakthrough, which enables infrared and visible green nanosecond pulses to be produced by a single dual-mode cavity, reducing complexity and resulting in a more elegant and up-to-date combo laser design."
In addition to the SLT and YAG combination laser, the Fusion integrates smoothly with Quantel’s Vitra Monospot and Multispot pattern-scanning retina laser systems, offering comprehensive treatment options for multi-specialty practices to treat glaucoma, cataract and retina conditions in one laser platform.
Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic company that develops ocular disease treatment technologies. Quantel Medical is a division of Quantel, a developer of solid-state lasers for scientific and